Clinical trial • Phase III • Oncology
XmAb24306 for Relapsed/Refractory Multiple Myeloma|Multiple myeloma
Phase III trial of XmAb24306 for Relapsed/Refractory Multiple Myeloma|Multiple myeloma. 39 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Relapsed/Refractory Multiple Myeloma|Multiple myeloma
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 05-06-2024
- First CTIS Authorization Date
- 02-07-2024
Trial design
Phase III trial across 4 sites in Denmark, Greece, Spain and others.
- Target Sample Size
- 39
Eligibility
Recruits 39 Vulnerable population selected; no details on consent or assent handling provided in the source data..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent handling provided in the source data.
Recruitment
- Planned Sample Size
- 39
- Recruitment Window Months
- 43
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 43
Denmark
- Earliest CTIS Part Ii Submission Date
- 24-06-2024
- Latest Decision Or Authorization Date
- 23-06-2025
- Processing Time Days
- 364
- Number Of Sites
- 1
- Number Of Participants
- 6
Sites
- Site Name
- Lillebaelt Hospital
- Department Name
- Department of Hematology
- Principal Investigator Name
- Katrine Fladeland
- Principal Investigator Email
- Katrine.Fladeland.Iversen@rsyd.dk
- Contact Person Name
- Katrine Fladeland
- Contact Person Email
- Katrine.Fladeland.Iversen@rsyd.dk
- Number Of Participants
- 6
Greece
- Earliest CTIS Part Ii Submission Date
- 24-06-2024
- Latest Decision Or Authorization Date
- 02-03-2026
- Processing Time Days
- 616
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Alexandra Hospital
- Department Name
- "Department of Clinical Therapeutics"
- Principal Investigator Name
- Meletios-Athanasios Dimopoulos
- Principal Investigator Email
- mdimop@med.uoa.gr
- Contact Person Name
- Meletios-Athanasios Dimopoulos
- Contact Person Email
- mdimop@med.uoa.gr
- Number Of Participants
- 8
Spain
- Earliest CTIS Part Ii Submission Date
- 24-06-2024
- Latest Decision Or Authorization Date
- 07-07-2025
- Processing Time Days
- 378
- Number Of Sites
- 1
- Number Of Participants
- 17
Sites
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Servicio de Hematología
- Principal Investigator Name
- Paula Rodríguez
- Principal Investigator Email
- paurodriguez@unav.es
- Contact Person Name
- Paula Rodríguez
- Contact Person Email
- paurodriguez@unav.es
- Number Of Participants
- 17
Norway
- Earliest CTIS Part Ii Submission Date
- 24-06-2024
- Latest Decision Or Authorization Date
- 03-03-2026
- Processing Time Days
- 617
- Number Of Sites
- 1
- Number Of Participants
- 12
Sites
- Site Name
- Oslo University Hospital HF
- Department Name
- Oslo Myeloma Center
- Principal Investigator Name
- Fredrik Schjesvold
- Principal Investigator Email
- fschjesv@ous-hf.no
- Contact Person Name
- Fredrik Schjesvold
- Contact Person Email
- fschjesv@ous-hf.no
- Number Of Participants
- 12
Sponsor
Primary sponsor
- Full Name
- Genentech Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- XmAb24306
- Investigational Product Name
- Cevostamab
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)